| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cell, Tumor, and Stem Cell Biology |
1 Department of Urology, University of Michigan, Ann Arbor, Michigan; 2 Department of Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania; 3 Tianjin Medical University, Tianjin, China; and 4 Centocor, Inc., Radnor, Pennsylvania
Requests for reprints: Evan T. Keller, Department of Urology, RM 5304 CCGCB, 1500 East Medical Center Drive, Ann Arbor, MI 48109-0940. Phone: 734-615-0280; Fax: 734-936-9220; E-mail: etkeller{at}umich.edu.
Initially, prostate cancer is androgen dependent. However, most cases progress to an androgen-independent state through unknown mechanisms. Interleukin-6 (IL-6) has been associated with prostate cancer progression including activation of the androgen receptor (AR). To determine if IL-6 plays a role in the conversion of prostate cancer from androgen dependent to androgen independent, we established androgen-dependent LuCaP 35 human prostate cancer xenografts in nude mice, castrated the mice, and blocked IL-6 activity using a neutralizing antibody (CNT0328) for a period of 18 weeks. IL-6 inhibition increased survival of mice and inhibited tumor growth, as reflected by decreased tumor volume and prostate-specific antigen levels, compared with that in mice receiving isotype control antibody. To test the effect of IL-6 inhibition on the conversion from androgen dependent to androgen independent, tumor cells from the treated mice were assessed for their androgen dependence both in vitro and by implanting them into sham-operated or orchiectomized mice. Tumor cells derived from the isotype-treated animals converted to androgen-independent state, whereas tumor cells from the anti-IL-6 antibody-treated mice were still androgen dependent in vitro and in vivo. Although there was no difference in AR levels between the androgen-independent and androgen-dependent tumors, IL-6 inhibition promoted both apoptosis and inhibited cell proliferation in tumors and blocked the orchiectomy-induced expression of histone acetylases, p300 and CBP, which are AR cofactors. These data show that IL-6 contributes to the development of androgen independence in prostate cancer and suggest that it mediates this effect, in part, through modulation of p300 and CBP. (Cancer Res 2006; 66(6): 3087-95)
This article has been cited by other articles:
|
|
 |
|
  H. Ishiguro, K. Akimoto, Y. Nagashima, Y. Kojima, T. Sasaki, Y. Ishiguro-Imagawa, N. Nakaigawa, S. Ohno, Y. Kubota, and H. Uemura aPKC{lambda}/{iota} promotes growth of prostate cancer cells in an autocrine manner through transcriptional activation of interleukin-6 PNAS, September 22, 2009; 106(38): 16369 - 16374. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Malinowska, H. Neuwirt, I. T Cavarretta, J. Bektic, H. Steiner, H. Dietrich, P. L Moser, D. Fuchs, A. Hobisch, and Z. Culig Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor Endocr. Relat. Cancer, March 1, 2009; 16(1): 155 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zoubeidi, J. Rocha, F. Z. Zouanat, L. Hamel, E. Scarlata, A. G. Aprikian, and S. Chevalier The Fer Tyrosine Kinase Cooperates with Interleukin-6 to Activate Signal Transducer and Activator of Transcription 3 and Promote Human Prostate Cancer Cell Growth Mol. Cancer Res., January 1, 2009; 7(1): 142 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Lu, D. Nie, W. T. Witt, Q. Chen, M. Shen, H. Xie, L. Lai, Y. Dai, and J. Zhang Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3{beta} phosphorylation Mol. Cancer Ther., October 1, 2008; 7(10): 3203 - 3211. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Sharifi, E. M. Hurt, S. B. Thomas, and W. L. Farrar Effects of Manganese Superoxide Dismutase Silencing on Androgen Receptor Function and Gene Regulation: Implications for Castration-Resistant Prostate Cancer Clin. Cancer Res., October 1, 2008; 14(19): 6073 - 6080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. D. Lewis, A. Winter, T. F. Murphy, S. Tripathi, V. N. Pandey, and B. E. Barton STAT3 inhibition in prostate and pancreatic cancer lines by STAT3 binding sequence oligonucleotides: differential activity between 5' and 3' ends Mol. Cancer Ther., June 1, 2008; 7(6): 1543 - 1550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Tang, K. Kitisin, W. Jogunoori, C. Li, C.-X. Deng, S. C. Mueller, H. W. Ressom, A. Rashid, A. R. He, J. S. Mendelson, et al. Progenitor/stem cells give rise to liver cancer due to aberrant TGF-{beta} and IL-6 signaling PNAS, February 19, 2008; 105(7): 2445 - 2450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ancrile, K.-H. Lim, and C. M. Counter Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis Genes & Dev., July 15, 2007; 21(14): 1714 - 1719. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. D. Loberg, D. A. Bradley, S. A. Tomlins, A. M. Chinnaiyan, and K. J. Pienta The Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy CA Cancer J Clin, July 1, 2007; 57(4): 225 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nonn, D. Duong, and D. M. Peehl Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells Carcinogenesis, June 1, 2007; 28(6): 1188 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. V. Heemers, T. J. Sebo, J. D. Debes, K. M. Regan, K. A. Raclaw, L. M. Murphy, A. Hobisch, Z. Culig, and D. J. Tindall Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells Cancer Res., April 1, 2007; 67(7): 3422 - 3430. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
